$8.46
2.76% yesterday
NYSE, Oct 17, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock price

$8.46
-0.37 4.19% 1M
+3.00 54.95% 6M
+2.39 39.37% YTD
+4.74 127.42% 1Y
+2.88 51.61% 3Y
+5.45 181.06% 5Y
-6.55 43.64% 10Y
NYSE, Closing price Thu, Oct 17 2024
-0.24 2.76%
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Key metrics

Market capitalization $2.62b
Enterprise Value $5.35b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 118.81
EV/Sales (TTM) EV/Sales 2.06
P/S ratio (TTM) P/S ratio 1.01
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.37%
Revenue (TTM) Revenue $2.60b
EBIT (operating result TTM) EBIT $332.59m
Free Cash Flow (TTM) Free Cash Flow $45.01m
Cash position $49.62m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 0.95
EV/Sales forward 1.94
Short interest 1.76%
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
75%
Hold
25%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,598 2,598
12% 12%
100%
- Direct Costs 1,652 1,652
10% 10%
64%
946 946
16% 16%
36%
- Selling and Administrative Expenses 226 226
32% 32%
9%
- Research and Development Expense 163 163
3% 3%
6%
558 558
18% 18%
21%
- Depreciation and Amortization 225 225
5% 5%
9%
EBIT (Operating Income) EBIT 333 333
40% 40%
13%
Net Profit -175 -175
8,418% 8,418%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
Business Wire
9 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2024 Results on November 8, 2024.
Neutral
Business Wire
17 days ago
BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and Metsera, Inc. (“Metsera”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the effi...
Neutral
Business Wire
25 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease.
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 7,850
Founded 2002
Website www.amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today